Drug-induced social connection: both MDMA and methamphetamine increase feelings of connectedness during controlled dyadic conversations
In controlled semi‑structured dyadic conversations, both MDMA (100 mg) and methamphetamine (20 mg) increased participants' feelings of connectedness relative to placebo. Both drugs elevated oxytocin, but only MDMA's oxytocin increase correlated with subjective closeness, indicating similar behavioural effects may arise from different neuroendocrine mechanisms and demonstrating a sensitive method for measuring pro‑social drug effects in person.
Authors
- Harriet de Wit
- Richard Lee
Published
Abstract
MDMA is a stimulant-like drug with distinctive empathogenic effects. Its pro-social effects, such as feelings of connectedness, may contribute to both its popularity as a recreational drug and its apparent value as an adjunct to psychotherapy. However, little is known about the behavioral processes by which MDMA affects social interactions. This investigation examined the effects of MDMA (100 mg versus placebo; N = 18) on feelings of connectedness with an unfamiliar partner during a semi-structured casual conversation. A separate study examined the effects of a prototypic stimulant methamphetamine (MA; 20 mg versus placebo; N = 19) to determine the pharmacological specificity of effects. Oxytocin levels were obtained in both studies. Compared to placebo, both MDMA and MA increased feelings of connection with the conversation partners. Both MDMA and MA increased oxytocin levels, but oxytocin levels were correlated with feeling closer to the partner only after MDMA. These findings demonstrate an important new dimension of the pro-social effects of MDMA, its ability to increase feelings of connectedness during casual conversations between two individuals. Surprisingly, MA had a similar effect. The findings extend our knowledge of the social effects of these drugs, and illustrate a sensitive method for assessing pro-social effects during in-person dyadic encounters.
Research Summary of 'Drug-induced social connection: both MDMA and methamphetamine increase feelings of connectedness during controlled dyadic conversations'
Introduction
Molla and colleagues frame MDMA as a stimulant-like compound with pronounced empathogenic and pro-social effects that may underlie both its recreational popularity and its emerging therapeutic utility, particularly as an adjunct in psychotherapy for post-traumatic stress disorder. The introduction notes that while animal and some human laboratory work have shown MDMA increases social approach, sociability and socioemotional processing, few controlled studies have examined how MDMA affects actual in-person social interactions, whether such effects are pharmacologically specific, or which physiological mechanisms (for example, oxytocin release) might mediate them. This paper reports two parallel within-subject, double-blind studies designed to address that gap. Study 1 tested the effects of MDMA (100 mg versus placebo; initial N = 18) and Study 2 tested methamphetamine (MA; 20 mg versus placebo; initial N = 19) on feelings of connectedness during a semi-structured 45-minute conversation with a previously unknown, same-sex partner. Salivary oxytocin and cardiovascular and subjective measures were also obtained to explore physiological correlates and the pharmacological specificity of any pro-social effects.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topic
- Authors
- APA Citation
Molla, H., Lee, R., Lyubomirsky, S., & de Wit, H. (2023). Drug-induced social connection: both MDMA and methamphetamine increase feelings of connectedness during controlled dyadic conversations. Scientific Reports, 13(1). https://doi.org/10.1038/s41598-023-43156-0
References (13)
Papers cited by this study that are also in Blossom
Bershad, A. K., Miller, M. A., Baggot, M. J. et al. · Journal of Psychopharmacology (2016)
Mitchell, J., Bogenschutz, M. P., Lilienstein, A. et al. · Nature Medicine (2021)
Bedi, G., Hyman, D., De Wit, H. · Biological Psychiatry (2010)
´dric, C., Hysek, M., Schmid, Y. et al. · Social Cognitive and Affective Neuroscience (2013)
Kirkpatrick, M. G., Lee, R., Wardle, M. C. et al. · Neuropsychopharmacology (2014)
Kuypers, K. P. C., Dolder, P. C., Ramaekers, J. G. et al. · Journal of Psychopharmacology (2017)
Holze, F., Vizeli, P., Müller, F. et al. · Neuropsychopharmacology (2019)
Dumont, G., Sweep, F., van der Steen, R. et al. · Social Neuroscience (2009)
Kirkpatrick, M. G., Francis, S. M., Lee, R. et al. · Psychoneuroendocrinology (2014)
Wardle, M. C., De Wit, H. · Psychopharmacology (2014)
Show all 13 referencesShow fewer
Kamilar-Britt, P., Bedi, G. · Neuroscience and Biobehavioral Reviews (2015)
Dolder, P. C., Müller, F., Schmid, Y. et al. · Psychopharmacology (2017)
Watts, R., Kettner, H., Gandy, S. et al. · Psychopharmacology (2022)
Cited By (3)
Papers in Blossom that reference this study
Martinez, R. L., Radošić, N., Molla, H. et al. · Journal of Psychopharmacology (2025)
Avram, M., Fortea, L., Wollner, L. et al. · Molecular Psychiatry (2024)
Zeifman, R. J., Kettner, H., Ross, S. et al. · European Journal of Psychotraumatology (2024)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.